Menu
Back to Journals » Neuropsychiatric Disease and Treatment » Volume 9
Role of oral teriflunomide in the management of multiple sclerosis
Authors Tanasescu R, Evangelou N, Constantinescu CS
Received 23 January 2013
Accepted for publication 18 March 2013
Published 22 April 2013 Volume 2013:9 Pages 539—553
DOI https://doi.org/10.2147/NDT.S31248
Review by Single anonymous peer review
Peer reviewer comments 4
Radu Tanasescu,1,2 Nikos Evangelou,1 Cris S Constantinescu1
1Academic Division of Clinical Neurology, University of Nottingham, Nottingham, UK; 2Department of Neurology, Colentina Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Abstract: The landscape of the treatment of relapsing–remitting multiple sclerosis is changing fast. Several oral treatments have shown benefit and generate much interest because of the convenience of their administration. Two oral compounds, fingolimod and teriflunomide, have been approved in relapsing–remitting multiple sclerosis, while others have completed Phase III trials and are awaiting review for registration. Teriflunomide is a pyrimidine synthesis inhibitor with selective immunomodulatory and immunosuppressive properties that have shown consistent efficacy in clinical trials, and a good safety profile. This paper provides an overview of the mechanisms of action and efficacy and safety results from clinical trials with this drug. The role of teriflunomide in the treatment of relapsing–remitting multiple sclerosis is discussed.
Keywords: teriflunomide, multiple sclerosis, oral drugs, clinical trials
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.